RotoGro buzzes on new strategic Affinity
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
ASX ag-tech cannabis play, RotoGro International (ASX:RGI), was up a little over 10% on the back of some intriguing news on Monday.
Fellow pot-stock, Affinity Energy and Health (ASX:AEB), which is the latest medical cannabis play to receive approval to establish a medicinal cannabis cultivation and manufacturing facility in Malta, has elected to use RotoGro’s patented hydroponic technology.
RGI's proven tech is key to AEB’s plans. This technology can allow for up to nine times the surface area for growing compared to traditional growing techniques, while allowing for 5.5 harvests per year.
Affinity will be allotted 2200 square metres of industrial land to construct and operate a fully automatic, controlled environment, hydroponic cultivation, manufacturing and distribution facility.
The number of ASX companies granted such approvals is fairly short at this stage — this news therefore represents a considerable milestone for AEB.
C$7.5 billion-capped Canadian weed producer, Aurora Cannabis (TSX:ACB | NYSE:ACB), is among an exclusive group of companies that were issued a letter of intent by Maltese investment body, Malta Enterprise.
As a member of the European Union, Malta provides access to more than 500 million people who live in the 23 member countries that have legalised medical cannabis.
RGI’s technology can achieve these kinds of results through the use of stackable, rotating growing beds that are expected to produce 3000kg of cannabis bud per annum once all units are installed.
AEB’s facility will have an initial 15 growing units, and will meet the EU good manufacturing practice (GMP) standards. It also expects to expand to 175 units over the next three years.
RGI updated the market in early November regarding the ongoing trials afoot at its state-of-the-art research and development facility in Ontario, Canada.
The key news revolved around significantly increased cannabis yields, which have consistently outperformed traditional ‘flat deck’ style systems occupying the same floor space.
To date, pot grown with the RotoGro Hydroponic Garden System has consistently yielded 7–9 pounds (3-4kg) of dry final flower product per harvest. This compares to 2.8 pounds (1.3kg) typically achieved with flat deck systems.
The ASX small cap designed and built the Ontario facility in order to cultivate both pot and perishable foods, via the use of two grow rooms – an on-site laboratory; germination and propagation rooms; and lastly, a control centre for the remote monitoring of growing facilities around the world (a component of RGI’s growing management services).
AEB’s Maltese approval complements its global medicinal cannabis strategy which includes strategic alliances with key industry bodies and R&D partners. Affinity's application for an Australian medical cannabis licence is also currently being processed by the Australian government. Separately, it is working with Austrade and Colombia’s ProColombia to submit a licence application for the cultivation, manufacture and sale of medical cannabis in Colombia.
AEB also recently executed an MoU with The University of Sydney in August to support its medicinal cannabis research and development activities in Australia.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
